Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy
Protagenic Therapeutics (NASDAQ: PTIX) just pulled off a biotech plot twist worthy of a season finale.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$0.81 | 8,000 | $6,480.00 | 45,815 | 2023-10-12 | Filing | |
$0.72 | 8,000 | $5,760.00 | 151,260 | 2022-05-18 | Filing | |
$0.71 | 23,000 | $16,330.00 | 143,260 | 2022-05-17 | Filing | |
$2.29 | 1,000 | $2,290.00 | 120,260 | 2021-04-30 | Filing | |
$2.29 | 1,000 | $2,290.00 | 119,260 | 2021-04-29 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 0 | $0 | 0% | |
2. | 0 | $0 | 0% | |
3. | 0 | $0 | 0% |